Patents by Inventor Challa S.S.R. Kumar

Challa S.S.R. Kumar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8414678
    Abstract: A method for generating metallic nanomaterials using acetylenic-bridged metal-carbonyl complexes as a precursor allows control of nanoparticle properties. The novel method produced metallic nanomaterials resistant to oxidation.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: April 9, 2013
    Assignee: Board of Supervisors of Lousiana State University And Agricultural and Mechanical College
    Inventors: Challa S. S. R. Kumar, Rohini M. de Silva, Josef Hormes
  • Publication number: 20100135845
    Abstract: A method for generating metallic nanomaterials using acetylenic-bridged metal-carbonyl complexes as a precursor allows control of nanoparticle properties. The novel method produced metallic nanomaterials resistant to oxidation.
    Type: Application
    Filed: September 14, 2007
    Publication date: June 3, 2010
    Inventors: Challa S.S.R. Kumar, Rohini M. de Silva, Josef Hormes
  • Publication number: 20090169478
    Abstract: A non-invasive in vivo technique is disclosed, useful for example in detecting cancers and micrometastases. The technique may be used to selectively deliver drugs to target cells such as tumors, metastases, micrometastases, and individual malignant cells. Ligands with specificity for a target cell receptor, and optionally drug molecules as well, are covalently bound to magnetic nanoparticles, either directly or through a spacer molecule. The ligand precludes the need for a separate coating layer. For example, human breast cancer cells express receptors both for luteinizing hormone/chorionic gonadotropin (LH/CG), and for luteinizing hormone releasing hormone (LHRH). These cells can be specifically targeted by iron oxide nanoparticles covalently linked to LH/CG or LHRH. The nanoparticles are incorporated into the cancer cells through receptor-mediated endocytosis. The specific accumulation in targeted cancer cells enhances resolution for imaging, therapy, or both.
    Type: Application
    Filed: August 4, 2006
    Publication date: July 2, 2009
    Applicant: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY
    Inventors: Carola Leuschner, Challa S.S.R. Kumar, William Hansel, Josef Hormes
  • Publication number: 20090061006
    Abstract: Nanoparticle compositions and methods are disclosed for the sustained release of small molecules, such as pharmaceutical compounds in vivo, for example ligand-lytic peptide conjugates. The construction of the nanoparticles helps to prevent self-aggregation of the molecules, and the consequent loss of effectiveness. The system employs layer-by-layer self-assembly of biocompatible polyelectrolyte layers, and layers of charged small molecules such as drug molecules, to form a multilayer nanoparticle in which the drug or other small molecule itself acts as one of the alternating charged layers in the multilayer assembly. The small molecules can then be released over time in a sustained manner. The LbL nano-assemblies can specifically target cancers, metastases, or other diseased tissues, while minimizing side effects.
    Type: Application
    Filed: March 28, 2007
    Publication date: March 5, 2009
    Inventors: Carola Leuschner, Yuri M. Lvov, Challa S.S.R. Kumar